Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081263 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Phase 2 study of Cervical Carcinoma and Stage 0 Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT00081263: Completed Phase 2 study of Cervical Carcinoma and Stage 0 Cervical Cancer, sponsored by Gynecologic Oncology Group.
NCT00081263 is a Phase 2 study of Cervical Carcinoma and Stage 0 Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 130 participants, below the 530-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081263, a Phase 2 study of Cervical Carcinoma and Stage 0 Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia.
Primary Outcome
Whether or not patients with CIN 2/3 or CIN 3 upon entry experience a complete remission (or partial regression to CIN 1) in the post-treatment excisional biopsy.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Celecoxib
Study Locations (20)
Indiana
- Elkhart Clinic - Elkhart
- Michiana Hematology Oncology PC-Elkhart - Elkhart
- Elkhart General Hospital - Elkhart
- Community Howard Regional Health - Kokomo
- IU Health La Porte Hospital - La Porte
- Michiana Hematology Oncology PC-Mishawaka - Mishawaka
- Saint Joseph Regional Medical Center-Mishawaka - Mishawaka
- Michiana Hematology Oncology PC-Plymouth - Plymouth
- Memorial Hospital of South Bend - South Bend
- Michiana Hematology Oncology PC-South Bend - South Bend
- Northern Indiana Cancer Research Consortium - South Bend
- Michiana Hematology Oncology PC-Westville - Westville
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Michigan
- Borgess Medical Center - Kalamazoo
- Bronson Methodist Hospital - Kalamazoo
Arizona
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Illinois
- Carle Clinic-Urbana Main - Urbana
Maryland
- Union Hospital of Cecil County - Elkton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00081263 record still lists
NCT00081263 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 530-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Cervical Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00081263 names 20 study sites across 7 states, led by Indiana, Delaware, Michigan.
Frequently Asked Questions
What is clinical trial NCT00081263 about?
NCT00081263 is a clinical study titled "Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia". This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have c...
What is the current status of trial NCT00081263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2005-06.
What conditions does trial NCT00081263 study?
This clinical trial studies the following conditions: Cervical Carcinoma, Stage 0 Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2/3.
What interventions are being tested in trial NCT00081263?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00081263?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081263 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Delaware, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00081263's enrollment target sits among peer trials
130 13th of 25 higher than 13 of 25 other Cervical Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
RECRUITING · Phase 2
-
HPV Vaccine, Imiquimod, and Metformin Combination Trial
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia